EGFR and non-small cell lung carcinoma: However, data from several early studies conducted simultaneously with EGFR-TKIs and ICIs in patients with NSCLC were disappointing (88–91), showing high toxicity due to adverse events, such as interstitial lung disease and elevated liver enzymes (89, 90).